康宁杰瑞(09966.HK)首次实现了年度盈利。这家公司预计2024年实现净利润不少于1.5亿元,相较2023年亏损2.11亿元,成功扭亏。这一转变主要归因于三项授权合作,尤其是2024年9月与石药集团的ADC药物JSKN003授权交易,康宁杰瑞得以收取4亿元预付款。此外,2024年1月和6月,康宁杰瑞分别与Glenmark公司、ArriVent BioPharma达成合作,总金额分别达7亿美元和...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.